Oncomine Myeloid MRD Assays | Thermo Fisher Scientific

More comprehensive, more informative, more streamlined myeloid MRD detection

The Ion Torrent Oncomine Myeloid MRD Assays (RUO) on the Ion GeneStudio S5 System is a complete NGS testing solution for myeloid measurable residual disease (MRD) research. Highly sensitive AmpliSeq HD technology enables a limit of detection as low as 0.05% allele frequency.

Unlike traditional methods, NGS allows you to obtain informative data across a broad range of biomarkers simultaneously. A DNA and an RNA assay enable comprehensive assessment of genetic alterations, including SNVs, indels, and gene fusions. This streamlined approach to MRD analysis also features a complete informatics and reporting solution that simplifies data analysis and interpretation

Download infographic

On Demand Webinar: Genomic profiling from initial assessment to detection of measurable residual disease (MRD): how NGS can rapidly deliver key insights for myeloid neoplasms.

Dr. Bevan Tandon will review ongoing research in his laboratory using the Oncomine Myeloid Assay GX, an NGS-based test capable of delivering results in just 1-2 days. He will also share his experience with the upcoming Oncomine Myeloid MRD Assay (RUO), a highly sensitive NGS test for measurable residual disease (MRD) assessment that can identify mutations occurring at very low frequencies. Dr. Tandon will share recent analytical data from his team and offer his perspective on the value of NGS in hematopathology studies.

Watch webinar on demand

Bevan Tandon, MD

Director, Hematopathology and Molecular Pathology

MRD Assay content summary

The assays feature DNA and RNA targets for myeloid MRD analysis, allowing simultaneous profiling of single nucleotide variants (SNVs), insertions and deletions (indels), tandem duplications, and key gene fusions.

These carefully curated targets are relevant for all categories of myeloid neoplasms, including Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Myeloproliferative Neoplasms (MPN) samples.

DNA panel

33 genes, including 2 full genes and FLT3-ITDs
Optional 22-amplicon micro-haplotype panel for
chimerism analysis

DNA Assay - Gene Targets
ABL1	FLT3**	NRAS	TP53*
ASXL1	GATA2	PHF6	U2AF1
BCOR	IDH1	PTPN11	WT1
BRAF	IDH2	RUNX1
CALR	JAK2	SETBP1
CBL	KIT	SF3B1
CEBPA*	KRAS	SH2B3
CSF3R	MPL	SRSF2
DNMT3A	MYD88	STAG2
EZH2	NPM1	TET2

RNA panel

42 fusion driver genes
990 unique fusions
6 genes with exon splicing variants
5 expression control genes

RNA Assay - Fusion Driver Genes				Expression Controls	Exon Splicing Variants
ABL1	FUS	MYBL1	RARA	ABL1	KMT2A
ABL2	GLIS2	MYH11	RARB	GUSB	RUNX1
ALK	HMGA2	NOTCH1	RARG	PSMB2	NOTCH1
BCL2	JAK2	NTRK1	RET	PUM1	ETV6
BRAF	KAT6A (MOZ)	NTRK2	RUNX1	TRIM27	IKZF1
CCND1	KAT6B	NTRK3	TAL1		NTRK1
CREBBP	KMT2A (includes PTD)*	NUP214	TCF3
CSF1R	MECOM	NUP98	TCF4
EGFR	MLLT10	PAX5	TFE3
ETV6	MRTFA (MLK1)	PDGFRA	ZNF384
FGFR1		PDGFRB

Chimerism analysis

An optional 22-amplicon DNA panel is included for chimerism analysis in post–allogeneic stem cell transplantation (allo-HSCT) research samples.

This innovative NGS technique measures the ratio of donor/recipient DNA down to 0.2% allele frequency. Unlike traditional methods that rely on qualitative analysis, NGS provides digital quantification of allele mixtures to identify low-frequency, disease-associated markers with high sensitivity.

Streamlined workflow

The Oncomine Myeloid MRD Assays (RUO) include a fully integrated workflow based on the Ion GeneStudio S5 System. The entire process can be completed in 2–3 days with roughly 2 hours of hands-on time.

Explore the Ion GeneStudio S5 System

Integrated informatics and reporting

The solution includes an integrated analysis pipeline that allows labs to easily analyze samples without needing deep informatics expertise typically required for other assays.

Easily visualize allele frequencies for target genes over a time series using Ion Reporter analysis tools.